Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
101 EUR | +0.60% | -0.30% | +7.05% |
30/04 | GERRESHEIMER AG : Jefferies reaffirms its Buy rating | ZD |
29/04 | Gerresheimer AG acquired minority stake in RxCap Inc. | CI |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company is in debt and has limited leeway for investment
- The firm trades with high earnings multiples: 24.39 times its 2024 earnings per share.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.05% | 3.73B | B+ | ||
-3.72% | 184B | C+ | ||
-2.60% | 107B | C | ||
-3.79% | 67.78B | A | ||
+2.66% | 50.66B | B- | ||
+16.39% | 47.64B | B- | ||
+4.60% | 41.12B | B+ | ||
+1.38% | 26.3B | B | ||
+1.52% | 26.04B | A- | ||
-1.17% | 24.71B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GXI Stock
- Ratings Gerresheimer AG